Welcome to our dedicated page for Fennec Pharmaceuticals news (Ticker: FENC), a resource for investors and traders seeking the latest updates and insights on Fennec Pharmaceuticals stock.
Fennec Pharmaceuticals Inc. reports developments as a commercial-stage specialty pharmaceutical company focused on PEDMARK® (sodium thiosulfate injection), a therapy used to reduce the risk of cisplatin-induced ototoxicity in pediatric patients with localized, non-metastatic solid tumors. The company also markets the product in Europe and the United Kingdom under the PEDMARQSI® name and has disclosed a licensing arrangement for commercialization in additional non-U.S. markets.
Recurring news themes include PEDMARK product sales and financial results, commercialization updates, scientific abstracts, investigator-sponsored and real-world studies in cancer patients receiving cisplatin-based chemotherapy, product exclusivity and patent matters, and equity compensation actions under Nasdaq rules.
Fennec Pharmaceuticals (NASDAQ:FENC) granted inducement incentive stock options to one new non-executive employee under its 2026 Equity Inducement Plan. The award covers 15,000 common shares at an exercise price of $9.06 per share, with a ten-year term and time-based vesting.
Fennec Pharmaceuticals (NASDAQ:FENC) approved an inducement grant of 10,000 incentive stock options for a new non-executive employee under its 2026 Equity Inducement Plan, effective June 15, 2026.
The options have a $9.00 exercise price, a 10-year term, and three-year, time-based vesting in line with Nasdaq Listing Rule 5635(c)(4).
Fennec (NASDAQ:FENC)/b) reported voting results from its Annual General and Special Meeting held June 10, 2025. Shareholders elected five director nominees, each receiving at least 93.62% of votes cast. Investors also approved auditor appointment, executive compensation and amendments to the 2020 Equity Incentive Plan with strong majorities.
Fennec Pharmaceuticals (NASDAQ:FENC) announced new independent research on PEDMARK at the 2026 ASCO Annual Meeting. Four studies span pediatric, adolescent, young adult, and adult cancer patients.
Data include a Japanese Phase 2/3 trial showing reduced cisplatin-induced hearing loss and real-world studies supporting feasible, ≥6-hour delayed dosing without compromising cisplatin’s antitumor activity.
Fennec Pharmaceuticals (NASDAQ:FENC) granted stock options under Nasdaq Listing Rule 5635(c)(4) as inducement awards to three new non-executive employees. On May 11, 2026, the board’s Compensation Committee approved options for an aggregate 50,000 common shares under the 2026 Equity Inducement Plan.
The options have a $9.75 exercise price, a 10-year term, and vest over three years, with one-third vesting after one year and the remainder vesting monthly over 24 months, subject to continued employment.
Fennec Pharmaceuticals (NASDAQ:FENC) reported Q1 2026 net revenues of $15.1 million, a 73% year-over-year increase, driven by broader PEDMARK sales, including new AYA accounts. Net income was $0.2 million (EPS $0.01) versus a $1.2 million loss in Q1 2025. Cash and equivalents rose to $40.1 million.
Selling and marketing expenses increased to $11.4 million while G&A declined to $3.2 million. Fennec initiated a third institution-led PEDMARK study in AYA and adult head and neck and testicular cancers, and four PEDMARK abstracts will appear at the 2026 ASCO Annual Meeting.
Fennec Pharmaceuticals (NASDAQ: FENC) will release Q1 2026 financial results before U.S. market open on Thursday, May 14, 2026. Management will host a conference call and live webcast at 8:30 a.m. ET. A replay will be archived on the company website for 30 days.
Fennec Pharmaceuticals (NASDAQ: FENC) announced four abstracts evaluating PEDMARK® (sodium thiosulfate) were accepted to the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago. Two items are poster presentations and two are abstract-only publications.
PEDMARK is approved for pediatric patients one month and older and carries a NCCN 2A recommendation for adolescent and young adult patients. Full abstracts will be available on the ASCO website on May 21, 2026 at 5:00 p.m. ET.
Fennec Pharmaceuticals (NASDAQ:FENC) announced the University of Arizona Cancer Center will conduct an investigator-sponsored Phase I/II study evaluating PEDMARK® (sodium thiosulfate) as an otoprotectant in adolescent/young adult and adult patients with head and neck and testicular cancers receiving cisplatin.
The release notes PEDMARK® is approved for pediatric patients one month and older and holds a NCCN 2A recommendation for AYA patients. Fennec cited two other recent institution-led studies at Tampa General Hospital and City of Hope; additional investigator-initiated studies are under review.
Fennec Pharmaceuticals (NASDAQ:FENC) announced inducement grants under Nasdaq Listing Rule 5635(c)(4). On March 31, 2026 the company granted incentive stock options to 24 new non-executive employees covering 377,500 shares under its 2026 Equity Inducement Plan.
All ISOs carry an exercise price of $5.77 (closing price on March 30, 2026), a 10-year term, and vest one-third after one year then monthly over the next 24 months, subject to continued employment.